{"DataElement":{"publicId":"2431562","version":"1","preferredName":"Other Breast Cancer Histopathologic Grade System Name Text","preferredDefinition":"The commonly used name of the scoring system used for histopathologic grading of an invasive breast carcinoma, when a grading system other than the Nottingham system is used.","longName":"2431356v1.0:2432587v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2431356","version":"1","preferredName":"Other Invasive Breast Carcinoma Histopathologic Grade Grading System","preferredDefinition":"Different than the one(s) previously specified or mentioned.:A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women. --2003:The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior_definition pending","longName":"2431282v1.0:2431229v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2431282","version":"1","preferredName":"Other Invasive Breast Carcinoma Histopathologic Grade","preferredDefinition":"Different than the one(s) previously specified or mentioned.:A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women. --2003:The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior","longName":"C17649:C9245:C18000","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Invasive Breast Carcinoma","conceptCode":"C9245","definition":"A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DCF287-1586-3AE1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2431229","version":"1","preferredName":"Grading System","preferredDefinition":"definition pending","longName":"C48224","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Grading System","conceptCode":"C48224","definition":"A morphologic classification system of malignant tumors, usually relating to disease progression and clinical outcome.  It is based upon the presence or absence of several morphologic parameters, including tumor cell necrosis, cytologic atypia, nuclear pleomorphism and mitotic figures, the architectural infiltrating patterns, and the degree of tumor cell differentiation.  Malignant tumors usually are graded I-III.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DCE451-6154-3394-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2222502","version":"1","preferredName":"UML DEFAULT CD","preferredDefinition":"Default Conceptual Domain for UML Loader","longName":"UML DEFAULT CD","context":"caCORE","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5E53F3B-47A4-52D1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-04-29","modifiedBy":"DWARZEL","dateModified":"2021-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DE02E1-E1AA-417D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Permission to Release DEC granted by primary curator in 8/2008.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2432587","version":"1","preferredName":"Findings Text","preferredDefinition":"Descriptive text used to enumerate additional non-coded pathologic observations._The words of something written.","longName":"2432587v1.0","context":"NCIP","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2183782","version":"1","preferredName":"NCIP","preferredDefinition":"Cancer Biomedical Informatics Grid","longName":"NCIP","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DACB2549-3BE3-73F7-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-19","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234203","version":"1","preferredName":"Text","preferredDefinition":"Text; the words of something written.","longName":"C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F89B-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CAP PROTOCOLS:College of American Pathologists Cancer Protocols","workflowStatus":"RELEASED","registrationStatus":"Application","id":"061284D5-1A6A-0705-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-21","endDate":null,"createdBy":"CROWLEYR","dateCreated":"2005-11-21","modifiedBy":"CURTIST","dateModified":"2010-09-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2534075","version":"1.2","longName":"caTISSUE CAE","context":"NCIP","ClassificationSchemeItems":[{"publicId":"10000562","version":"1","longName":"edu.pitt.cabig.cae.domain.breast","context":"NCIP"}]},{"publicId":"2857187","version":"1","longName":"CAP Cancer Checklists","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812063","version":"1","longName":"edu.upmc.opi.cabig.caties.cap.domain.breast","context":"NCIP"}]}],"AlternateNames":[{"name":"edu.pitt.cabig.cae.domain.breast.OtherBreastCancerHistologicGrade.systemName","type":"UML Qualified Attr","context":"NCIP"},{"name":"OtherBreastCancerHistologicGrade:systemName","type":"UML Class:UML Attr","context":"NCIP"},{"name":"edu.upmc.opi.cabig.caties.cap.domain.breast.OtherBreastCancerHistopathologicGrade.systemName","type":"UML Qualified Attr","context":"NCIP"},{"name":"OtherBreastCancerHistopathologicGrade:systemName","type":"UML Class:UML Attr","context":"NCIP"}],"ReferenceDocuments":[{"name":"Specify other grading system.","type":"Preferred Question Text","description":"Specify other grading system.","url":null,"context":"NCIP"}],"origin":"CAP PROTOCOLS:College of American Pathologists Cancer Protocols","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DE5895-DDAF-5B38-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-23","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"REEVESD","dateModified":"2009-07-16","changeDescription":"Permission to Release CDE granted by primary curator, Linda Schmandt, in 8/2008","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}